Status: Recruiting
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells. The main question it aims to answer is whether the combination of medicines can get rid of metastatic tumors in participants with non-castrate, recurrent, oligometastatic prostate cancer. Participants will undergo: * Treatment with pTVG-HP * Treatment with Nivolumab * Radiation Therapy
Participants needed: 14
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: University of Wisconsin, MadisonUpdated: Mar 11, 2026Locations: 1
Eligibility criteria
Participants must be at least 18 years of age with a histologic diagnosis of ade... [+11]
Small cell or other variant prostate cancer histology [+9]